UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancer treatments, has announced its participation in the Guggenheim Securities Healthcare Innovation Conference. The company will engage in a fireside chat on November 12, 2024, at 3:00 PM ET in Boston, MA. The event will include one-on-one investor meetings and will be accessible via public webcast through UroGen's Investor Relations website, with replay available for 90 days.
UroGen Pharma (Nasdaq: URGN), una compagnia biotech focalizzata sui trattamenti per il cancro uroteliale e specializzato, ha annunciato la sua partecipazione alla Guggenheim Securities Healthcare Innovation Conference. L'azienda parteciperà a una chiacchierata informale il 12 novembre 2024, alle 15:00 ET a Boston, MA. L'evento includerà incontri individuali con gli investitori e sarà accessibile tramite webcast pubblico sul sito web delle Relazioni con gli Investitori di UroGen, con replay disponibile per 90 giorni.
UroGen Pharma (Nasdaq: URGN), una empresa biotecnológica centrada en tratamientos para el cáncer urotelial y especializado, ha anunciado su participación en la Guggenheim Securities Healthcare Innovation Conference. La compañía participará en un chat informal el 12 de noviembre de 2024, a las 3:00 PM ET en Boston, MA. El evento incluirá reuniones individuales con inversores y será accesible a través de un webcast público en el sitio web de Relaciones con Inversores de UroGen, con reposición disponible durante 90 días.
UroGen Pharma (Nasdaq: URGN)는 배뇨세포 및 특수 암 치료에 집중하는 생명공학 회사로, Guggenheim Securities Healthcare Innovation Conference에 참가할 것이라고 발표했습니다. 이 회사는 2024년 11월 12일 오후 3시 ET에 매사추세츠주 보스턴에서 진행되는 화상 대화에 참여할 것입니다. 이 행사는 1대1 투자자 회의가 포함되며, UroGen의 투자자 관계 웹사이트를 통해 공개 웹캐스트에 접속 가능하며, 90일 동안 다시 볼 수 있습니다.
UroGen Pharma (Nasdaq: URGN), une entreprise biopharmaceutique axée sur les traitements du cancer urotélial et spécialisé, a annoncé sa participation à la Guggenheim Securities Healthcare Innovation Conference. L'entreprise participera à une discussion informelle le 12 novembre 2024, à 15h00 ET à Boston, MA. L'événement comprendra des réunions individuelles avec des investisseurs et sera accessible par webcast public via le site des Relations Investisseurs d'UroGen, avec une rediffusion disponible pendant 90 jours.
UroGen Pharma (Nasdaq: URGN), ein Biotech-Unternehmen, das sich auf uroteliale und spezielle Krebsbehandlungen konzentriert, hat seine Teilnahme an der Guggenheim Securities Healthcare Innovation Conference bekannt gegeben. Das Unternehmen wird am 12. November 2024, um 15:00 Uhr ET in Boston, MA, an einem Gespräch am Kamin teilnehmen. Die Veranstaltung umfasst persönliche Investorenmeetings und wird über einen öffentlichen Webcast auf der Investor Relations-Website von UroGen zugänglich sein, mit einer Wiederholung, die 90 Tage verfügbar ist.
- None.
- None.
Fireside Chat on November 12, 2024 at 3:00 PM ET
Guggenheim Securities Healthcare Innovation Conference
Date / Time: |
November 12, 2024 at 3:00 PM ET |
Format: |
Fireside Chat and 1x1 investor meetings |
Location: |
|
Webcast Link: |
A live public webcast from the conference will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105753655/en/
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: UroGen Pharma Ltd.
FAQ
When is UroGen Pharma (URGN) presenting at the Guggenheim Securities Healthcare Conference 2024?
How can I watch UroGen Pharma's (URGN) Guggenheim Conference presentation?
What type of presentation will UroGen Pharma (URGN) give at the Guggenheim Healthcare Conference?
Where is the 2024 Guggenheim Securities Healthcare Innovation Conference with UroGen Pharma (URGN) being held?
